July 28, 2021
Diversity and Inclusion for Clinical Trials in PAD
In the United States, more than 8-million people over the age of 40 have Peripheral Artery Disease (PAD). PAD is caused by a buildup of plaque in the arteries that reduces the flow of blood to other parts of the body, such as your legs. Symptoms include painful cramps in your legs after walking or climbing stairs, numbness or weakness, and sores on your feet and legs that won’t heal. PAD can result in problems with walking and (in extreme cases) amputation. Medical experts are committed to raising awareness about PAD through patient education.
Abbott is a global healthcare company that recently launched the LIFE-BTK trial…clinical research to evaluate a potential therapy for Critical Limb Ischemia (CLI), a more severe form of PAD. Abbott makes everything from nutritional supplements to life-saving medical devices. They are changing the world of clinical trials and making them more accessible to underserved communities who could benefit the most from them…one patient at a time.
Abbott’s goal is to bring more inclusivity and accessibility to racial and ethnic groups that have long been underrepresented in these critically important clinical studies.
The LIFE-BTK trial is a model of inclusion and diversity in clinical trials.
In order for a wound to heal efficiently, the skin has a sophisticated reparative process that must occur. Stay tuned.
Join host Beth Troutman as she learns about off episodes and dyskinesia in Parkinson's disease.
Join correspondent Olga Villaverde as she explores innovations in the early detection of lung cancer.